AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23661841 — intervention group
Group type: COMPARATOR
Intervention: 40 mg elemental iron as ferrous sulphate (Control)
Number of subjects: 100
Study 19301937 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 146
Study 19301937 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 146
Study 17522789 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac low-dose infusion
Number of subjects: 22
Study 17522789 — intervention group
Group type: COMPARATOR
Intervention: Extemporaneous boluses of NSAIDs (CTRL)
Number of subjects: 22
Study 12665701 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 30 mg once weekly with vitamin D 400 iu daily and 1200 mg of calcium daily
Number of subjects: 150
Study 12665701 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 30 mg once weekly
Number of subjects: 150
Study 11059477 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8781308 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 8781308 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 1532684 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic cement VP 862 (containing fluoride)
Number of subjects: 10
Study 1532684 — intervention group
Group type: COMPARATOR
Intervention: Heliosit‐Orthodontic (no fluoride)
Number of subjects: 10
Study 1532684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride release from fluoride adhesive in water
Number of subjects: 10
Study 1532684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride release in human saliva at pH 7
Number of subjects: 10
Study 1532684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride release in saliva at pH 4
Number of subjects: 10
Study 6370428 — intervention group
Group type: EXPERIMENTAL
Intervention: vincristine-prednisone alternating with cytarabine-cyclophosphamide (Arm B)
Number of subjects: 347
Study 6370428 — intervention group
Group type: COMPARATOR
Intervention: vincristine-prednisone (Arm A)
Number of subjects: 347
Study 2858709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for two years
Number of subjects: 1285
Study 2858709 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group with systemic therapy reserved until the time of relapse
Number of subjects: 1285
Study 30395350 — intervention group
Group type: EXPERIMENTAL
Intervention: One-level reduction in WHO drinking risk level
Number of subjects: 1142
Study 30395350 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level reduction in WHO drinking risk level
Number of subjects: 1142
Study 26798655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (DR screening and monitoring via telehealth)
Number of subjects: 1024
Study 26798655 — intervention group
Group type: COMPARATOR
Intervention: Control practices (usual care)
Number of subjects: 1024
Study 22336221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² every 21 days)
Number of subjects: 663
Study 22336221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study 20090319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 150
Study 20090319 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 150
Study 18346537 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0
Study 18346537 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16845252 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily
Number of subjects: 20
Study 16845252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 20
Study 16845252 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg plus Ramipril 2.5 mg daily
Number of subjects: 20
Study 14557145 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency left-sided repetitive transcranial magnetic stimulation (HFL-TMS) applied daily for 4 weeks (20 5-second trains at 10 Hz)
Number of subjects: 60
Study 14557145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency right-sided repetitive transcranial magnetic stimulation (LFR-TMS) applied daily for 4 weeks (five 60-second trains at 1 Hz)
Number of subjects: 60
Study 14557145 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (coil angled at 45 degrees from the scalp)
Number of subjects: 60
Study 10945509 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 32
Study 10945509 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 32
Study 8883115 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg calcium as calcium citrate malate per day)
Number of subjects: 112
Study 8883115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 8883115 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg calcium as calcium citrate malate per day) in subjects with above-median Tanner scores
Number of subjects: 112
Study 8883115 — intervention group
Group type: COMPARATOR
Intervention: Placebo in subjects with above-median Tanner scores
Number of subjects: 112
Study 1576854 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 22)
Number of subjects: 38
Study 1576854 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 38
Study 3880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation once a day at varying dosing times (8 a.m., noon, and 8 p.m.)
Number of subjects: 66
Study 3880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation at 8 a.m.
Number of subjects: 66
Study 3880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation at 8 p.m.
Number of subjects: 66
Study 3880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation with evening dosing
Number of subjects: 66
Study 3880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation with morning or noon dosing
Number of subjects: 66
Study 3880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation
Number of subjects: 66
Study 31136263 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP gel (3.5 ml ± 1.5 ml) injected at bone-tendon interface
Number of subjects: 69
Study 31136263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP gel)
Number of subjects: 69
Study 29065364 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention
Number of subjects: 40
Study 29065364 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 40
Study 26465137 — intervention group
Group type: COMPARATOR
Intervention: Extensive casein hydrolyzate (eHF-C)
Number of subjects: 2252
Study 26465137 — intervention group
Group type: COMPARATOR
Intervention: Partial whey hydrolyzate (pHF-W)
Number of subjects: 2252
Study 26465137 — intervention group
Group type: COMPARATOR
Intervention: Extensive whey hydrolyzate (eHF-W)
Number of subjects: 2252
Study 26465137 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cow's milk formula (CMF)
Number of subjects: 2252
Study 25186834 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading-dose rosuvastatin 40 mg given 4 h before PCI
Number of subjects: 143
Study 25186834 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose rosuvastatin 10 mg given 4 h before PCI
Number of subjects: 143
Study 22480536 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bipolar disorder excluded from trials due to medical conditions
Number of subjects: 10
Study 20660279 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry supplementation (50 g freeze-dried blueberries, approximately 350 g fresh blueberries)
Number of subjects: 48
Study 20660279 — intervention group
Group type: COMPARATOR
Intervention: Control (960 mL water)
Number of subjects: 48
Study 18778199 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐Interferon alpha‐2a (180 microg weekly subcutaneously)
Number of subjects: 143
Study 18778199 — intervention group
Group type: COMPARATOR
Intervention: Peg‐Interferon alpha‐2b (1.5 microg/kg weekly subcutaneously)
Number of subjects: 143
Study 15947736 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxic tent (NH)
Number of subjects: 8
Study 15947736 — intervention group
Group type: COMPARATOR
Intervention: Normal ambient environment (BL)
Number of subjects: 8
Study 15947736 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxic tent (NN)
Number of subjects: 8
Study 12764339 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine in one eye
Number of subjects: 102
Study 12764339 — intervention group
Group type: COMPARATOR
Intervention: Sterile water in the other eye
Number of subjects: 102
Study 12764339 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of pupillary dilation
Number of subjects: 102
Study 12764339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestalt judgment of pupillary dilation
Number of subjects: 102
Study 11783239 — intervention group
Group type: EXPERIMENTAL
Intervention: Taozhi Zhipu Mixture (TZM)
Number of subjects: 396
Study 11783239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TZM)
Number of subjects: 396
Study 8896482 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost regimen (intravenous at the beginning of the operation and three daily 6-hour infusions postoperatively, with an intragraft injection at completion of the bypass)
Number of subjects: 528
Study 8896482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 8896482 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost regimen
Number of subjects: 528
Study 8896482 — intervention group
Group type: COMPARATOR
Intervention: Iloprost regimen and Placebo
Number of subjects: 528
Study 2053784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised acidic salbutamol solution
Number of subjects: 34
Study 2053784 — intervention group
Group type: COMPARATOR
Intervention: Placebo of equal acidity (pH 3.9)
Number of subjects: 34
Study 6406443 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (Wellbutrin)
Number of subjects: 94
Study 6406443 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (Elavil, Endep)
Number of subjects: 94
Study 6406443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 30957534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 64
Study 28677349 — intervention group
Group type: EXPERIMENTAL
Intervention: HBB 20 mg
Number of subjects: 299
Study 28677349 — intervention group
Group type: COMPARATOR
Intervention: Anisodamine 10 mg
Number of subjects: 299
Study 26582355 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted operation method for minimal-invasive total hip replacement (CAS FF)
Number of subjects: 60
Study 26582355 — intervention group
Group type: COMPARATOR
Intervention: Conventional total hip replacement (CON)
Number of subjects: 60
Study 23383973 — intervention group
Group type: EXPERIMENTAL
Intervention: Xilei-san enema
Number of subjects: 35
Study 23383973 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone enema
Number of subjects: 35
Study 21306830 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline positive expectancies
Number of subjects: 5782
Study 21306830 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressed mood
Number of subjects: 5782
Study 21306830 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectancies
Number of subjects: 5782
Study 21306830 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood
Number of subjects: 5782
Study 19682118 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination of staff
Number of subjects: 40
Study 19682118 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 40
Study 17287478 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320
Study 17287478 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320
Study 17287478 — intervention group
Group type: EXPERIMENTAL
Intervention: four weekly 45 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320
Study 17287478 — intervention group
Group type: EXPERIMENTAL
Intervention: four weekly 90 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320
Study 17287478 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 320
Study 17287478 — intervention group
Group type: EXPERIMENTAL
Intervention: interleukin-12/23 monoclonal antibody
Number of subjects: 320
Study 15111188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 161
Study 15111188 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study 11700905 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic neighborhood defined by associations
Number of subjects: 0
Study 11700905 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic neighborhood defined by global co-occurrences
Number of subjects: 0
Study 9228873 — intervention group
Group type: EXPERIMENTAL
Intervention: FES leg cycle exercise (FES-LCE)
Number of subjects: 11
Study 9228873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid exercise training
Number of subjects: 11
Study 8424383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-omega 6 polyunsaturated fatty acid diet (8.4 en% polyunsaturated fatty acids, 8.3 en% linoleic acid)
Number of subjects: 0
Study 8424383 — intervention group
Group type: COMPARATOR
Intervention: Lower-omega 6 polyunsaturated fatty acid diet (3.1 en% polyunsaturated fatty acids, 3.0 en% linoleic acid)
Number of subjects: 0
Study 3301120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK) 1‐h infusion of 1,500,000 IU
Number of subjects: 64
Study 3301120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 64
Study 29314866 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day spearmint extract
Number of subjects: 90
Study 29314866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26259895 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable contraception
Number of subjects: 2018
Study 26259895 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pills
Number of subjects: 2018
Study 26259895 — intervention group
Group type: COMPARATOR
Intervention: Condoms
Number of subjects: 2018
Study 26259895 — intervention group
Group type: COMPARATOR
Intervention: Other methods (intrauterine device, traditional methods, natural methods)
Number of subjects: 2018
Study 25933511 — intervention group
Group type: EXPERIMENTAL
Intervention: LDB-CPR
Number of subjects: 912
Study 25933511 — intervention group
Group type: COMPARATOR
Intervention: M-CPR
Number of subjects: 912
Study 24124961 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec and insulin aspart (IDegAsp)
Number of subjects: 112
Study 24124961 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 112
Study 20110274 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment with follow-up visits to provide IDA education
Number of subjects: 189
Study 20110274 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment with no follow-up
Number of subjects: 189
Study 20110274 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study 19568702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4% q.i.d.
Number of subjects: 61
Study 19568702 — intervention group
Group type: COMPARATOR
Intervention: Bromfenac 0.09% b.i.d.
Number of subjects: 61
Study 17826496 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 643
Study 17826496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 15156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy followed by standard level I and II axillary dissection
Number of subjects: 0
Study 15156950 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy without dissection unless metastatic disease is noted
Number of subjects: 0
Study 15156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary dissection
Number of subjects: 0
Study 15156950 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 11532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency responding during 'Go/No-go' task (response inhibition)
Number of subjects: 0
Study 11532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency responding during 'oddball' task (target detection)
Number of subjects: 0
Study 11532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency responding during two-alternative forced-choice task (response selection)
Number of subjects: 0
Study 11532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Response inhibition condition
Number of subjects: 0
Study 11532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with errors committed
Number of subjects: 0
Study 9692448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of L-arginine administered during the first 30 minutes of cardioplegic arrest
Number of subjects: 50
Study 9692448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-arginine supplementation)
Number of subjects: 50
Study 9692448 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine group
Number of subjects: 50
Study 9692448 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 9692448 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine group and control group
Number of subjects: 50
Study 9692448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardioplegia
Number of subjects: 50
Study 9692448 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardioplegia
Number of subjects: 50
Study 8747049 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 232
Study 8747049 — intervention group
Group type: COMPARATOR
Intervention: SUZI
Number of subjects: 232
Study 8747049 — intervention group
Group type: COMPARATOR
Intervention: Both SUZI and ICSI
Number of subjects: 232
Study 2193493 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 92
Study 2193493 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 92
Study 2193493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 20218011 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 2.9 and 16 min
Number of subjects: 16
Study 20218011 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 62 and 229 min
Number of subjects: 16
Study 20218011 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro burst time
Number of subjects: 16
Study 20218011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean time to peak plasma level
Number of subjects: 16
Study 20218011 — intervention group
Group type: EXPERIMENTAL
Intervention: All capsule formulations
Number of subjects: 16
Study 28956942 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 352
Study 28956942 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Dialogue Intervention (WDI)
Number of subjects: 352
Study 28956942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ACT and WDI
Number of subjects: 352
Study 28956942 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 352
Study 28300529 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccination
Number of subjects: 0
Study 28300529 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 vaccination
Number of subjects: 0
Study 25808074 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (15, 20, or 30 mg)
Number of subjects: 32
Study 25808074 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 32
Study 26162817 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 83
Study 26162817 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 83
Study 24622525 — intervention group
Group type: EXPERIMENTAL
Intervention: RN-SBIRT training program
Number of subjects: 0
Study 24622525 — intervention group
Group type: COMPARATOR
Intervention: Self-directed Web site on alcohol-related care
Number of subjects: 0
Study 21055743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with closely approximated legs
Number of subjects: 29
Study 21055743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with closely approximated legs with a lap pad
Number of subjects: 29
Study 21055743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with legs apart at a 70° angle with a lap pad
Number of subjects: 29
Study 19055224 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal periosteal pedicle graft (MPP)
Number of subjects: 15
Study 19055224 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 15
Study 16549967 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intermittent HAART (4 weeks on/8 weeks off), n = 23
Number of subjects: 46
Study 16549967 — intervention group
Group type: COMPARATOR
Intervention: Continuous HAART
Number of subjects: 46
Study 12729123 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Ullevaal hip screws
Number of subjects: 278
Study 12729123 — intervention group
Group type: COMPARATOR
Intervention: Two Hansson hook-pins
Number of subjects: 278
Study 12729123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 278
Study 12729123 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative drill penetration of the femoral head
Number of subjects: 278